Zachary BessetteLocalized | November 17, 2023
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
Read More
Emily MenendezLocalized | November 10, 2023
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
Zachary BessetteAdvanced Imaging | November 7, 2023
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Katy MarshallLocalized | October 26, 2023
Enzalutamide combined with leuprolide led to higher rates of MFS than leuprolide alone.
Zachary BessetteESMO 2023 | October 18, 2023
ArteraAI Prostate—a multimodal, AI-derived prognostic test—was successfully validated in the phase 3 STAMPEDE trials.
Zachary BessetteESMO 2023 | October 18, 2023
New understandings of PROs related to enzalutamide-plus-leuprolide-acetate treatment for high-risk BCR nmHSPC.
Emily MenendezASTRO 2023 | October 6, 2023
According to new data, concerns surrounding the efficacy of 19-20 Gy single-dose HDR-BT as a monotherapy may be unfounded.
Emily MenendezASTRO 2023 | October 3, 2023
While the low-dose arm required more salvage therapy, dose-escalated RT resulted in lower rates of DM.
Zachary BessetteASTRO 2023 | October 2, 2023
Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC.
Zachary BessetteASTRO 2023 | October 2, 2023
Intermediate-risk PC can be treated as effectively with SBRT as with conventional radiation, according to 5-year results.
Emily MenendezLocalized | September 25, 2023
Bladder cancers that develop after radiation tend to be more aggressive and are more likely to be sarcomatoid variant.
Emily MenendezLocalized | September 25, 2023
Higher tumor fraction after chemohormonal therapy was also linked to aggressive pathologic features and poor outcomes.
Zachary BessetteAdvanced Imaging | September 13, 2023
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Emily MenendezLocalized | September 8, 2023
Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic.
Akhil Abraham Saji, MDLocalized | September 5, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Emily MenendezProstate Cancer | August 2, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Akhil Abraham Saji, MDLocalized | July 31, 2023
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
Emily MenendezLocalized | July 27, 2023
An AI-based model predicts which patients with localized prostate cancer would better benefit from the use of ADT.